ReviewEndocrinology2018
Gut Microbiota: FFAR Reaching Effects on Islets.
Review in Endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- A Multidisciplinary Approach of Type 1 Diabetes: The Intersection of Technology, Immunotherapy, and Personalized Medicine.Journal of clinical medicine · 2025Review
- Naturopathic Management to Taper Off Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: A Case Report.Integrative medicine (Encinitas, Calif.) · 2025Article
- Probing and manipulating the gut microbiome with chemistry and chemical tools.Gut microbiome (Cambridge, England) · 2025Review
- Exploring the effects of dietary inulin in rainbow trout fed a high-starch, 100% plant-based diet.Journal of animal science and biotechnology · 2024Article
- Probiotic for Pancreatic β-Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Editorial: Gut physiology-microbes and inflammatory diseases.Frontiers in physiology · 2023Article
- Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis.Frontiers in endocrinology · 2023Review
- Central and peripheral regulations mediated by short-chain fatty acids on energy homeostasis.Translational research : the journal of laboratory and clinical medicine · 2022Review
- Intestinal FFA3 mediates obesogenic effects in mice on a Western diet.American journal of physiology. Endocrinology and metabolism · 2022Article
- Obesity-induced elevated palmitic acid promotes inflammation and glucose metabolism disorders through GPRs/NF-κB/KLF7 pathway.Nutrition & diabetes · 2022Article
- Metabolic Homeostasis: It's All in the Timing.Endocrinology · 2022Review
- Role of gut microbiota in the pathogenesis and treatment of diabetes mullites: Advanced research-based review.Frontiers in microbiology · 2022Review
- From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators.Microbiome · 2021Review
- FFAR from the Gut Microbiome Crowd: SCFA Receptors in T1D Pathology.Metabolites · 2021Review
- New insights into the links between anti-diabetes drugs and gut microbiota.Endocrine connections · 2021Review
- New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes.Drug design, development and therapy · 2021Review
- Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes.Current nutrition reports · 2020Review
- Free fatty acid receptor 3 differentially contributes to β-cell compensation under high-fat diet and streptozotocin stress.American journal of physiology. Regulatory, integrative and comparative physiology · 2020Article
- Controversial Roles of Gut Microbiota-Derived Short-Chain Fatty Acids (SCFAs) on Pancreatic β-Cell Growth and Insulin Secretion.International journal of molecular sciences · 2020Review
- Acetate Revisited: A Key Biomolecule at the Nexus of Metabolism, Epigenetics, and Oncogenesis - Part 2: Acetate and ACSS2 in Health and Disease.Frontiers in physiology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The G protein-coupled receptors, free fatty acid (FFA) receptors 2 and 3 (FFA2 and FFA3), belonging to the free fatty acid receptor (FFAR) class, sense a distinct class of nutrients, short chain fatty acids (SCFAs). These receptors participate in both immune and metabolic regulation. The latter includes a role in regulating secretion of metabolic hormones. It was only recently that their role in pancreatic β cells was recognized; these receptors are known now to affect not only insulin secretion but also β-cell survival and proliferation. These observations make them excellent potential therapeutic targets in type 2 diabetes. Moreover, expression on both immune and β cells makes these receptors possible targets in type 1 diabetes. Furthermore, SCFAs are generated by gut microbial fermentative activity; therefore, signaling by FFA2 and FFA3 represents an exciting novel link between the gut microbiota and the β cells. This review enumerates the role of these receptors in β cells revealed so far and discusses possible roles in clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.